Mardi Dier - Net Worth and Insider Trading

Mardi Dier Net Worth

The estimated net worth of Mardi Dier is at least $4 Million dollars as of 2024-04-25. Mardi Dier is the CFO & Executive Vice President of Ultragenyx Pharmaceutical Inc and owns about 66,695 shares of Ultragenyx Pharmaceutical Inc (RARE) stock worth over $3 Million. Mardi Dier is the EVP, CFO & CBO of Portola Pharmaceuticals Inc and owns about 66,733 shares of Portola Pharmaceuticals Inc (PTLA) stock worth over $1 Million. Mardi Dier is also the Director of Prelude Therapeutics Inc and owns about 10,000 shares of Prelude Therapeutics Inc (PRLD) stock worth over $40,100. Besides these, Mardi Dier also holds Acelyrin Inc (SLRN) . Details can be seen in Mardi Dier's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Mardi Dier has not made any transactions after 2023-05-09 and currently still holds the listed stock(s).

Transaction Summary of Mardi Dier

To

Mardi Dier Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mardi Dier owns 6 companies in total, including Ultragenyx Pharmaceutical Inc (RARE) , Prelude Therapeutics Inc (PRLD) , and Portola Pharmaceuticals Inc (PTLA) among others .

Click here to see the complete history of Mardi Dier’s form 4 insider trades.

Insider Ownership Summary of Mardi Dier

Ticker Comapny Transaction Date Type of Owner
RARE Ultragenyx Pharmaceutical Inc 2022-10-14 CFO & Executive Vice President
PRLD Prelude Therapeutics Inc 2020-09-29 director
PTLA Portola Pharmaceuticals Inc 2020-07-02 EVP and CFO
ADMS Adamas Pharmaceuticals Inc 2020-06-03 director
ORIC ORIC Pharmaceuticals Inc 2020-04-23 director
SLRN Acelyrin Inc 2023-05-09 CFO and CBO

Mardi Dier Latest Holdings Summary

Mardi Dier currently owns a total of 4 stocks. Among these stocks, Mardi Dier owns 66,695 shares of Ultragenyx Pharmaceutical Inc (RARE) as of October 14, 2022, with a value of $3 Million and a weighting of 69.38%. Mardi Dier owns 66,733 shares of Portola Pharmaceuticals Inc (PTLA) as of April 4, 2019, with a value of $1 Million and a weighting of 28.9%. Mardi Dier also owns 10,000 shares of Prelude Therapeutics Inc (PRLD) as of September 29, 2020, with a value of $40,100 and a weighting of 0.96%. The other 1 stocks Acelyrin Inc (SLRN) have a combined weighting of 0.76% among all his current holdings.

Latest Holdings of Mardi Dier

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
RARE Ultragenyx Pharmaceutical Inc 2022-10-14 66,695 43.31 2,888,227
PTLA Portola Pharmaceuticals Inc 2019-04-04 66,733 18.03 1,203,196
PRLD Prelude Therapeutics Inc 2020-09-29 10,000 4.01 40,100
SLRN Acelyrin Inc 2023-05-09 7,306 4.32 31,562

Holding Weightings of Mardi Dier


Mardi Dier Form 4 Trading Tracker

According to the SEC Form 4 filings, Mardi Dier has made a total of 4 transactions in Ultragenyx Pharmaceutical Inc (RARE) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in Ultragenyx Pharmaceutical Inc is the sale of 1,629 shares on October 14, 2022, which brought Mardi Dier around $65,421.

According to the SEC Form 4 filings, Mardi Dier has made a total of 0 transactions in Portola Pharmaceuticals Inc (PTLA) over the past 5 years. The most-recent trade in Portola Pharmaceuticals Inc is the sale of 40,486 shares on April 4, 2019, which brought Mardi Dier around $2 Million.

According to the SEC Form 4 filings, Mardi Dier has made a total of 1 transactions in Prelude Therapeutics Inc (PRLD) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Prelude Therapeutics Inc is the acquisition of 10,000 shares on September 29, 2020, which cost Mardi Dier around $190,000.

More details on Mardi Dier's insider transactions can be found in the Insider Trading History of Mardi Dier table.

Insider Trading History of Mardi Dier

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Mardi Dier Trading Performance

GuruFocus tracks the stock performance after each of Mardi Dier's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mardi Dier is 97.52%. GuruFocus also compares Mardi Dier's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mardi Dier within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Mardi Dier's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Mardi Dier

Average Return

7.14%

Average return per transaction

Outperforming Transactions

100%

1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -1.83 97.52 -15.21 7.14 -52.45 -52.5
Relative Return to S&P 500(%) -3.63 87.42 -27.51 -23.56 -56.92 -61.23

Mardi Dier Ownership Network

Ownership Network List of Mardi Dier

No Data

Ownership Network Relation of Mardi Dier


Mardi Dier Owned Company Details

What does Ultragenyx Pharmaceutical Inc do?

Who are the key executives at Ultragenyx Pharmaceutical Inc?

Mardi Dier is the CFO & Executive Vice President of Ultragenyx Pharmaceutical Inc. Other key executives at Ultragenyx Pharmaceutical Inc include EVP and Chief Medical Officer Eric Crombez , CBO & Senior Vice President Thomas Richard Kassberg , and EVP and General Counsel Karah Herdman Parschauer .

Ultragenyx Pharmaceutical Inc (RARE) Insider Trades Summary

Over the past 18 months, Mardi Dier made no insider transaction in Ultragenyx Pharmaceutical Inc (RARE). Other recent insider transactions involving Ultragenyx Pharmaceutical Inc (RARE) include a net sale of 5,605 shares made by Theodore Alan Huizenga , a net sale of 127,435 shares made by Emil D Kakkis , and a net sale of 54,366 shares made by Thomas Richard Kassberg .

In summary, during the past 3 months, insiders sold 69,133 shares of Ultragenyx Pharmaceutical Inc (RARE) in total and bought 0 shares, with a net sale of 69,133 shares. During the past 18 months, 243,293 shares of Ultragenyx Pharmaceutical Inc (RARE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 243,293 shares.

Ultragenyx Pharmaceutical Inc (RARE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Ultragenyx Pharmaceutical Inc Insider Transactions

No Available Data

Mardi Dier Mailing Address

Above is the net worth, insider trading, and ownership report for Mardi Dier. You might contact Mardi Dier via mailing address: C/o Acelyrin, Inc., 4149 Liberty Canyon Rd., Agoura Hills Ca 91301.

Discussions on Mardi Dier

No discussions yet.